Annals of Surgery · 2009 · 159 citations · 29 references
MedicineCancer BiologyOncologyStem Cell BiologyTissue EngineeringTumor MicroenvironmentMesenchymal Stem Cell TherapyMesenchymal Stromal Cell TherapyPancreatic CancerStem Cell TumorigenicityTissue Engineering With Stem CellsTumor-stroma InteractionsBone Marrow-derived Mesenchymal Stromal CellsMesenchymal Stem Cell Gene TherapyTumor Microenvironment Effects
In Brief Objective: To analyze the efficacy of engineered mesenchymal stem cell based therapy directed towards pancreatic tumor stroma. Summary Background Data: Mesenchymal stem cells (MSC) are actively recruited to tumor stroma where they enhance tumor growth and metastases. Upregulation of chemotactic cytokine (CCL5) by MSCs within the tumor stroma has been shown to play a central role in this process. Murine MSCs were engineered to express reporter genes or therapeutic genes under control of the CCL5 promoter and adoptively transferred into mice with growing pancreatic tumors. The effect on tumor growth and metastases was then evaluated. Methods: MSCs isolated from bone marrow of C57/Bl6 p53−/− mice were stably transfected with red fluorescent protein (RFP), enhanced green fluorescent protein (eGFP), or herpes simplex virus (HSV) thymidine kinase (Tk) gene driven by the RANTES promoter. MSCs were intravenously applied once per week over 3 weeks to mice carrying an orthotopic, syngeneic pancreatic Panc02 tumor. Results: eGFP and RFP signals driven by the CCL5 promoter were detected by fluorescence in treated pancreatic tumor samples. The HSV-Tk therapy group treated intraperitoneal with the prodrug ganciclovir 5 to 7 days after stem cell application lead to a 50% reduction of primary pancreatic tumor growth (P < 0.0003, student t test) and reduced liver metastases (0% vs. 60%). Conclusion: The active homing of MSCs into primary pancreatic tumor stroma and activation of the CCL5 promoter was verified using eGFP- and RFP-reporter genes. In the presence of ganciclovir, HSV-Tk transfected MSCs led to a significant reduction of primary pancreatic tumor growth and incidence of metastases. Murine mesenchymal stem cells, engineered to express reporter genes or therapeutic genes under the control of the CCL5 promoter, were adoptively transferred into mice with growing pancreatic tumors. In the presence of ganciclovir, Herpes simplex virus thymidine kinase transfected murine mesenchymal stem cells led to a significant reduction of primary pancreatic tumor growth and incidence of metastases.
29
Multilineage Potential of Adult Human Mesenchymal Stem Cells
Mark F. Pittenger, Alastair M. Mackay, Stephen C. Beck et al. · Science · 1999 · 21.1K citations
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Antoine E. Karnoub, Ajeeta B. Dash, Annie P. Vo et al. · Nature · 2007 · 3.2K citations
Medicine, Cell Biology, Oncology +12
Human Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas
Akira Nakamizo, Frank C. Marini, Toshiyuki Amano et al. · Cancer Research · 2005 · 1K citations
Medicine, Cell Biology, Oncology +8
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.
Matus Studeny, Frank C. Marini, Richard E. Champlin et al. · PubMed · 2002 · 907 citations
Medicine, Cell Biology, Oncology +17